Samsung C&T (SCT) and Samsung Electronics (SEC) have joined forces with Grail, a healthcare company, to advance the availability of Grail’s Galleri, a multi-cancer early detection (MCED) test, in the main Asian markets.
The companies have signed a binding letter of intent in this regard.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
By analysing a blood sample, the test can identify more than 50 types of cancer, prior to any symptoms manifesting.
As part of the collaboration, SCT and SEC have committed to an investment of $110m in Grail, with the purchase price set at $70.05 per share of common stock.
This investment hinges on the completion of definitive partnership agreements, customary closing conditions and obtaining the necessary regulatory clearances.
The transaction is set for completion in early 2026.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe partnership between Grail and Samsung C&T is poised to make the Galleri test exclusively available in South Korea, with prospects for expansion into other Asian markets such as Singapore and Japan.
In South Korea, and possibly in Singapore and Japan, SCT will act as the sole distributor of the Galleri test, provided certain conditions are met.
Initially, the Galleri tests will be conducted in Grail’s clinical laboratory in Research Triangle Park, North Carolina, US.
Additionally, SEC is exploring the possibility of further strategic partnerships with Grail, which may include supporting clinical research and integrating Samsung’s health data platform with Grail’s data, as well as technology.
Samsung Electronics mobile eXperience business digital health team head and senior vice-president Hon Pak said: “Our investment in and strategic cooperation with Grail is part of our vision to improve the health of billions of people.
“A potential collaboration with Grail could allow for the integration of our AI, our digital care platform and device ecosystem with Grail’s clinical genetic data and technology, which could allow us to provide a level of personalisation for our users to help them better understand their health.”
Latham & Watkins provided legal counsel to Grail, while Morgan Stanley & Co offered financial advice.
Samsung received guidance from BKL, E&Y Han Young and Covington & Burling for this initiative.
In June 2025, Grail reported top-line performance and safety outcomes from the pre-specified analysis of the Galleri test in its registrational PATHFINDER 2 trial.
